Related Experiment Video
Updated: May 16, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Vitamin K2 covalently binds to Bak and induces Bak-mediated apoptosis
Satoki Karasawa1, Motoki Azuma, Takeshi Kasama
1Department of Biological Information, Graduate School of Bioscience and Biotechnology Tokyo Institute of Technology, 4259 Nagatsuta, Midori-ku, Yokohama 226-8503, Japan.
Abstract:
Vitamin K2 (VK2, menaquinone) is known to have anticancer activity in vitro and in vivo. Although its effect is thought to be mediated, at least in part, by the induction of apoptosis, the underlying molecular mechanism remains elusive. Here, we identified Bcl-2 antagonist killer 1 (Bak) as a molecular target of VK2-induced apoptosis. VK2 directly interacts with Bak and induces mitochondrial-mediated apoptosis. Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for VK2-induced cytochrome c (cyt c) release and cell death. Moreover, VK2-2,3 epoxide, an intracellular metabolite of VK2, was shown to covalently bind to the cysteine-166 residue of Bak. Several lines of evidence suggested that the covalent attachment of VK2 is critical for apoptosis induction. Thus this study reveals a specific role for Bak in mitochondria-mediated apoptosis. This study also provides insight into the anticancer effects of VK2 and suggests that Bak may be a potential target of cancer therapy.
Insights
Vitamin K2 (VK2) induces cancer cell death by directly targeting the Bak protein, initiating apoptosis. This discovery reveals VK2
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Vitamin K2 (VK2) exhibits anticancer properties.
- The precise molecular mechanisms underlying VK2's anticancer effects, particularly apoptosis induction, are not fully understood.
Purpose of the Study:
- To elucidate the molecular targets and mechanisms of VK2-induced apoptosis.
- To identify specific proteins involved in VK2's anticancer activity.
Main Methods:
- Investigated VK2's interaction with apoptosis-related proteins.
- Utilized in vitro and in vivo models to study VK2's effects.
- Analyzed protein binding and functional assays to confirm molecular targets.
Main Results:
- Identified Bcl-2 antagonist killer 1 (Bak) as a direct molecular target of VK2.
- Demonstrated that VK2 directly interacts with Bak, inducing mitochondrial-mediated apoptosis.
- Showed that Bak, but not Bax, is essential for VK2-induced cytochrome c release and cell death.
- Confirmed that an intracellular VK2 metabolite covalently binds to Bak, crucial for apoptosis.
Conclusions:
- VK2 induces apoptosis specifically through Bak.
- This study reveals a novel mechanism of VK2 anticancer activity involving Bak.
- Bak emerges as a potential therapeutic target for cancer treatment using VK2.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
08:51Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling
Published on: June 25, 2015
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Apoptosis
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
Caspases
Cellular Injury V: Apoptosis and Autophagy